Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

• Main Authors: Juan Espinosa-Pereiro (Author), Samiksha Ghimire (Author), Marieke G. G. Sturkenboom (Author), Jan-Willem C. Alffenaar (Author), Margarida Tavares (Author), Sarita Aguirre (Author), Arturo Battaglia (Author), Gladys Molinas (Author), Teresa Tórtola (Author), Onno W. Akkerman (Author), Adrian Sanchez-Montalva (Author), Cecile Magis-Escurra (Author)
• Format: Book
• Published: MDPI AG, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those per...